What Are the Clinical Applications of EZH2 Inhibitors?
The most advanced EZH2 inhibitor, tazemetostat, has been approved by the FDA for the treatment of certain types of epithelioid sarcoma and follicular lymphoma. Clinical trials are also underway to evaluate the efficacy of EZH2 inhibitors in other cancers such as non-Hodgkin lymphoma and solid tumors. These inhibitors are being tested both as monotherapies and in combination with other cancer treatments, such as immune checkpoint inhibitors and chemotherapy.
